论文信息 - Anilinopyrazole as selective CDK2 inhibitors: design, synthesis, biological evaluation, and X-ray crystallographic analysis.

Anilinopyrazole as selective CDK2 inhibitors: design, synthesis, biological evaluation, and X-ray crystallographic analysis.

A novel series of anilinopyrazoles has been designed based on the X-ray crystal structure analysis. Most compounds from this series not only show sub-nanomolar IC(50) values for CDK2, but also demonstrate almost 1000-fold selectivity to other kinases including CDK1.

[1] S. Frye. Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. , 1999, Chemistry & biology.

[2] A. Fattaey,et al. CDK inhibition and cancer therapy. , 1999, Current opinion in genetics & development.

[3] L Meijer,et al. Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases. , 1999, Pharmacology & therapeutics.

[4] N. Jullian,et al. Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future. , 2002, Current topics in medicinal chemistry.

[5] L. Johnson,et al. Structural basis for control by phosphorylation. , 1997, Chemical reviews.

[6] P. A. Harris,et al. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis. , 2001, Journal of medicinal chemistry.

[7] J. Harper,et al. Cyclin-dependent kinases. , 2001, Chemical reviews.

[8] T. Hunter,et al. Oncogenic kinase signalling , 2001, Nature.

[9] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.

[10] P. Toogood. Cyclin‐dependent kinase inhibitors for treating cancer , 2001, Medicinal research reviews.

[11] K. Webster,et al. The therapeutic potential of targeting the cell cycle. , 1998, Expert opinion on investigational drugs.